Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.61 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12993155 | 0.84 | PYCR1 (0.56) | TAAR1AOC3SIGMAR1PYCR1 | |
| SCHEMBL25833522 | 0.79 | TAAR1 (0.71) | TAAR1AOC3SIGMAR1PYCR1HTR2A | |
| SCHEMBL25833470 | 0.78 | TAAR1 (0.65) | TAAR1AOC3SIGMAR1PYCR1HTR2A | |
| SCHEMBL3056908 | 0.77 | TAAR1 (1.00) | TAAR1AOC3SIGMAR1PYCR1 | |
| Hydrochloric Acid SCHEMBL8507687 | 0.75 | TAAR1 (0.96) | TAAR1AOC3SIGMAR1PYCR1 | |
| SCHEMBL19444655 | 0.75 | TAAR1 (0.59) | TAAR1AOC3SIGMAR1OPRM1OPRK1 | |
| SCHEMBL25852812 | 0.74 | TAAR1 (0.63) | TAAR1AOC3SIGMAR1DRD2DRD3 | |
| SCHEMBL14614771 | 0.74 | PYCR1 (0.51) | TAAR1AOC3SIGMAR1PYCR1 | |
| Ammonia Solution, Strong SCHEMBL9061818 | 0.71 | TAAR1 (0.50) | TAAR1AOC3SIGMAR1 | |
| SCHEMBL10678630 | 0.71 | SIGMAR1 (0.61) | AOC3SIGMAR1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | US | disclosed |
| EP-4212531-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2023-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | TAAR1 1183/4885AOC3 3111/4885SIGMAR1 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.